FDA Issues Vet Letter on Drug Librela Used to Control Pain in Dogs
The FDA's Center for Veterinary Medicine posted a letter alerting veterinarians of adverse health effects in dogs from ...
Popular dog arthritis medication Librela linked to pet illnesses, deaths, FDA says in urgent warning
Dangerous side effects from the injectable canine drug Librela — used to treat osteoarthritis joint pain — have been linked ...
FDA alerting vets about arthritis drug after hundreds of reports of health problems in dogs
The FDA is alerting veterinarians about reports of health problems in dogs, including hundreds of deaths, tied to a drug for ...
FDA alerting veterinarians after reports of health problems in dogs tied to arthritis drug
Channel 2 Action News has learned that the FDA is now alerting veterinarians about reports of health problems in dogs – ...
ConsumerAffairs5d
FDA cautions veterinarians about prescribing Librela for dogs
The U.S. Food and Drug Administration has warned veterinarians that an often-prescribed arthritis medication for dogs may be ...
Dog Arthritis Treatment Under Fire After Reports of Severe, Even Fatal, Side Effects
In a new report this week, the FDA highlighted several serious adverse events and deaths associated with the drug Librela.
Popular Arthritis Drug for Dogs May Have Severe Side Effects, F.D.A. Says
The agency recommended that the maker of Librela update its label to reflect the possibility of more serious adverse ...
todaysveterinarybusiness8d
Zoetis Responds to FDA’s ‘Dear Veterinarian’ Letter
The FDA has issued a “Dear Veterinarian” letter notifying practitioners about adverse events reported in dogs treated with ...
“Our dog suffered in the end.” Dog dies after receiving Librela injection
Joanna Freeman is still reeling after having to euthanize her eleven-year-old dog, Berkley, days after he was injected with ...
New York Post6d
Popular dog arthritis medication Librela linked to pet illnesses, deaths, FDA says in urgent warning
Dangerous side effects from the injectable canine drug Librela — used to treat osteoarthritis ... between January 2023 and March 2024, the FDA said in the cautionary letter, published Monday.